NEW YORK (GenomeWeb News) – Luminex said after the close of the market on Monday that its xTAG CYP2C19 kit has been cleared for marketing by the US Food and Drug Administration and has received the CE Mark in Europe.

The test is intended to aid physicians in determining treatment plans based on genetic variants in the P450 2C19 gene. CYP2C19 is a gene that encodes a phase one drug metabolizing enzyme. The CYP2C19 enzyme is responsible for metabolizing a number of prodrugs and drugs for treating ailments such as ulcers, seizures, malaria, and anxiety, Luminex said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.